Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01344447 · ClinicalTrials.gov registry record · Phase 3
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 479
- Enrollment target
NCT01344447 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 479 participants.
The verdict
NCT01344447, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 479 participants
- Enrollment target
Study Summary
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).
Interventions
- DRUG Gadobutrol (Gadovist, BAY86-4875)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2011-05-12 |
| Est. Completion | 2014-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01344447
The ClinicalTrials.gov registry entry for NCT01344447 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gadobutrol (Gadovist, BAY86-4875) is the first listed.
NCT01344447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01344447 about?
NCT01344447 is a clinical study titled "Gadobutrol Enhanced MRA of the Supra-aortic Vessels". Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will c...
What is the current status of trial NCT01344447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 479 participants. The study started on 2011-05-12. Estimated completion is 2014-05-28.
What interventions are being tested in trial NCT01344447?
The interventions under investigation include: Gadobutrol (Gadovist, BAY86-4875) (DRUG).
Who is sponsoring clinical trial NCT01344447?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.